Pfizer abruptly stopped development of its newest heart medicine in 2006, when clinical trials showed it was increasing patients’ risk of death.

Lessons from an $800-million drug flop may lead to a new genre of anti-cholesterol medicines

By American Chemical Society —— Bio and Archives--February 22, 2012

Health and Medicine | Comments | Back To Full Article

Chemical & Engineering News Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called “good cholesterol,” which removes cholesterol from the body. A report on how three new versions of medications in the same family as the failed torcetrapib appears in the current edition of Chemical & Engineering News, the news magazine of the American Chemical Society, the world’s largest scientific society.

Read Full Article...

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy

CFP Comments

Comments

Support Canada Free Press

Recommended by Canada Free Press